Other cancer characteristics, including age of onset, tumor size, overall stage, estrogen receptor, HER2 overexpression, nuclear grade, lymphovascular invasion, receipt of radiotherapy or hormonal therapy, did not show statistically significant difference in the BRCA mutation carriers, as compared with those without mutations. This evidence concerns the gene ERBB2 and neoplasm.